Zynex (NASDAQ:ZYXI) Announces Quarterly Earnings Results, Misses Estimates By $0.11 EPS

Zynex (NASDAQ:ZYXI - Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.11), Zacks reports. Zynex had a net margin of 2.49% and a return on equity of 13.05%.

Zynex Trading Down 2.4 %

Shares of Zynex stock traded down $0.17 during mid-day trading on Tuesday, hitting $7.00. 103,296 shares of the stock were exchanged, compared to its average volume of 112,010. The stock has a market capitalization of $222.92 million, a price-to-earnings ratio of 46.67 and a beta of 0.81. Zynex has a twelve month low of $5.44 and a twelve month high of $13.19. The company has a current ratio of 3.94, a quick ratio of 3.15 and a debt-to-equity ratio of 1.66. The company has a 50-day simple moving average of $7.74 and a 200 day simple moving average of $8.02.

Insider Activity

In other news, CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the sale, the chief financial officer now owns 19,738 shares of the company's stock, valued at $151,587.84. The trade was a 33.63 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 30,000 shares of company stock valued at $227,100 over the last 90 days. Insiders own 52.13% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a "buy" rating and set a $17.00 price target on shares of Zynex in a research note on Friday, December 6th.

Remove Ads

About Zynex

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.